Sight Sciences Inc (SGHT)
5.20
-0.33
(-5.97%)
USD |
NASDAQ |
Apr 16, 15:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 257.68M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -39.76% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.120 |
| Price to Book Value | 2.143 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2822 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |
| URL | https://www.sightsciences.com |
| Investor Relations URL | https://investors.sightsciences.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Mar. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |
| URL | https://www.sightsciences.com |
| Investor Relations URL | https://investors.sightsciences.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Mar. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |